Ken Griffin Galecto, Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$0.47 - $0.76 $16,489 - $26,663
35,083 Added 37.52%
128,584 $60,000
Q1 2024

May 15, 2024
BUY
$0.6 - $0.89 $12,640 - $18,750
21,068 Added 29.09%
93,501 $72,000
Q4 2023

Feb 14, 2024
BUY
$0.52 - $0.78 $37,665 - $56,497
72,433 New
72,433 $52,000
Q2 2023

Aug 14, 2023
SELL
$1.68 - $2.84 $4,393 - $7,426
-2,615 Reduced 53.9%
2,237 $5,000
Q1 2023

May 15, 2023
BUY
$1.21 - $2.86 $5,870 - $13,876
4,852 New
4,852 $9,000

Others Institutions Holding GLTO

# of Institutions
1
Shares Held
21.2K
Call Options Held
0
Put Options Held
0
View Full List

About Galecto, Inc.

GLTO Quotes by TradingView
  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $143M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email